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Abstract
Background:  Smoking remains the leading preventable cause of premature deaths. Several
pharmacological interventions now exist to aid smokers in cessation. These include Nicotine
Replacement Therapy [NRT], bupropion, and varenicline. We aimed to assess their relative efficacy
in smoking cessation by conducting a systematic review and meta-analysis.
Methods:  We searched 10 electronic medical databases (inception to Sept. 2006) and
bibliographies of published reviews. We selected randomized controlled trials [RCTs] evaluating
interventions for smoking cessation at 1 year, through chemical confirmation. Our primary
endpoint was smoking cessation at 1 year. Secondary endpoints included short-term smoking
cessation (~3 months) and adverse events. We conducted random-effects meta-analysis and meta-
regression. We compared treatment effects across interventions using head-to-head trials and
when these did not exist, we calculated indirect comparisons.
Results: We identified 70 trials of NRT versus control at 1 year, Odds Ratio [OR] 1.71, 95%
Confidence Interval [CI], 1.55–1.88, P =< 0.0001). This was consistent when examining all placebo-
controlled trials (49 RCTs, OR 1.78, 95% CI, 1.60–1.99), NRT gum (OR 1.60, 95% CI, 1.37–1.86)
or patch (OR 1.63, 95% CI, 1.41–1.89). NRT also reduced smoking at 3 months (OR 1.98, 95% CI,
1.77–2.21). Bupropion trials were superior to controls at 1 year (12 RCTs, OR1.56, 95% CI, 1.10–
2.21, P = 0.01) and at 3 months (OR 2.13, 95% CI, 1.72–2.64). Two RCTs evaluated the superiority
of bupropion versus NRT at 1 year (OR 1.14, 95% CI, 0.20–6.42).
Varenicline was superior to placebo at 1 year (4 RCTs, OR 2.96, 95% CI, 2.12–4.12, P =< 0.0001)
and also at approximately 3 months (OR 3.75, 95% CI, 2.65–5.30). Three RCTs evaluated the
effectiveness of varenicline versus bupropion at 1 year (OR 1.58, 95% CI, 1.22–2.05) and at
approximately 3 months (OR 1.61, 95% CI, 1.16–2.21). Using indirect comparisons, varenicline was
superior to NRT when compared to placebo controls (OR 1.66, 95% CI 1.17–2.36, P = 0.004) or
to all controls at 1 year (OR 1.73, 95% CI 1.22–2.45, P = 0.001). This was also the case for 3-month
data. Adverse events were not systematically different across studies.
Conclusion: NRT, bupropion and varenicline all provide therapeutic effects in assisting with
smoking cessation. Direct and indirect comparisons identify a hierarchy of effectiveness.
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Background
Smoking is the leading cause of preventable death in the
world[1]. Given the multitude of health benefits of smok-
ing cessation, considerable effort has been focused on
identifying mechanisms to assist smokers in quitting.
However, smoking cessation is challenging and behav-
ioural interventions have had only modest success [2].
Drug therapy has been increasingly relied upon to assist in
smoking cessation. The most common of these has been
nicotine replacement therapy [NRT] [3]. More recently,
attention has focused on the use of anti-depressant ther-
apy and specifically the agent bupropion[4]. Five new tri-
als have demonstrated the effectiveness of a new agent
with a novel mechanism of action, varenicline, in improv-
ing cessation rates [5-9].
How effective are pharmacologic smoking cessation ther-
apies? No systematic review and meta-analysis has exam-
ined this issue since the availability of information of the
newest agent. We conducted a meta-analysis of Rand-
omized Controlled Trials [RCTs] to identify the effective-
ness of the various pharmacological interventions in
improving cessation rates.
Methods
Eligibility criteria
Our primary outcome of interest was smoking cessation at
1 year. Our secondary outcomes were short-term smoking
cessation defined as 3 months after initiating treatment or
closest available data to that time point, within one
month. Our additional secondary outcome evaluated
adverse events. We included any RCT of NRT of any deliv-
ery method, bupropion or varenicline. We included only
RCTs of at least 1 years duration with chemical confirma-
tion of smoking cessation, as there is reason to doubt
patient self-report regarding addictions. Methods of
assessing smoking cessation also vary from study to study.
The most common method is self-report, however, this
can have false cessation rates as high as 30%[10]. False
reporting is most likely to occur in a trial setting or in
assessing smoking status after a medical event. In both sit-
uations the smoker is under considerable pressure to quit.
Laboratory tests are, therefore, often used to verify smok-
ing status, especially in clinical trials. Methods of biologi-
cal verification include serum and saliva thiocyanate
(SCN), expired carbon monoxide (CO), plasma, saliva
and urinary cotinine and plasma and urinary nicotine.
Each of these have various strengths and weaknesses[11].
Studies had to report smoking cessation as either sus-
tained abstinence at the time periods or point-prevalence
of abstinence. When both outcomes were available, we
considered sustained abstinence to be a superior clinical
marker of abstinence. We excluded non-RCTs, post-hoc
analyses, maintenance therapy, and studies that reported
outcomes as self-report.
Search strategy
In consultation with a medical librarian (PR), we estab-
lished a search strategy. We searched independently, in
duplicate, the following 10 databases (from inception to
September 10, 2006): MEDLINE, EMBASE, Cochrane
CENTRAL, AMED, CINAHL, TOXNET, Development and
Reproductive Toxicology, Hazardous Substances Data-
bank, Psych-info and Web of Science, databases that
included the full text of journals (OVID, ScienceDirect, and
Ingenta, including articles in full text from approximately
1700 journals since 1993). In addition, we searched the
bibliographies of published systematic reviews[3,12-
18,4,19] and health technology assessments[20]. Searches
were not limited by language, sex or age.
Study selection
Two investigators (EM, PW) working independently, in
duplicate, scanned all abstracts and obtained the full text
reports of records, that indicated or suggested that the
study was a RCT evaluating a smoking cessation therapy
on the outcomes of interest. After obtaining full reports of
the candidate trials (either in full peer-reviewed publica-
tion or press article) the same reviewers independently
assessed eligibility from full text papers.
Data collection
Two reviewers (PW, PD) conducted data extraction inde-
pendently using a standardized pre-piloted form. Review-
ers collected information about the smoking cessation
intervention tested, the population studied (age, sex,
underlying conditions), treatment dosages and dosing
schedules, the treatment effect at 1 year and at 3 months,
the specific measurement of abstinence (sustained or
point-prevalence), and the chemical confirmation meth-
ods. Study evaluation included general methodological
reporting quality features including allocation conceal-
ment, sequence generation, blinding status, intention-to-
treat, and appropriate descriptions of loss to follow-up.
Quality of reporting could be considered as analogous to
methodological quality if one assumes that failure to
report on a component of study design (for example
blinding) actually indicated that the component was not
employed. We entered the data into an electronic data-
base such that duplicate entries existed for each study;
when the two entries did not match, we resolved differ-
ences through discussion and consensus.
Data analysis
In order to assess inter-rater reliability on inclusion of arti-
cles, we calculated the Phi statistic (ϕ), which provides a
measure of inter-observer agreement independent of
chance[21]. We calculated the Odds Ratios [OR] andBMC Public Health 2006, 6:300 http://www.biomedcentral.com/1471-2458/6/300
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appropriate 95% Confidence Intervals [CIs] of outcomes
according to the number of events of abstinence reported
in the original studies or sub-studies. In circumstances of
zero outcome events in one arm of a trial, we added 1 to
each arm, as suggested by Sheehe[22]. We first pooled
studies of all NRT interventions versus all controls using
the DerSimonian-Laird random effects method,[23]
which recognizes and anchors studies as a sample of all
potential studies, and incorporates an additional
between-study component to the estimate of variabil-
ity[24]. We calculated the I2 statistic for each analysis as a
measure of the proportion of the overall variation that is
attributable to between-study heterogeneity[25]. Forest
plots are displayed for each primary analysis, showing
individual study effect measures with 95% CIs, and the
overall DerSimmonian-Laird pooled estimate. We then
conducted a meta-regression analysis on the NRT studies
with predictors of heterogeneity including the following
covariates: placebo control; reporting of sequence genera-
tion; reporting of allocation concealment; use of gum or
patch; and, method of chemical confirmation of absti-
nence. When the meta-regression indicated heterogeneity,
we conducted alternative sensitivity tests using z-tests to
determine differences between the studies reporting the
covariates to the pooled all-studies effect size. We addi-
tionally conducted separate pooled analyses of NRT ver-
sus placebo, gum versus control and patch versus control.
We conducted all analyses at 1 year and also at 3 months.
For bupropion trials, we pooled all bupropion trials
(standard and sustained-release) versus all controls and
conducted a meta-regression analysis using the following
covariates: placebo control; reporting of sequence genera-
tion; reporting of allocation concealment; method of
chemical confirmation of abstinence; and plans to quit.
We conducted separate meta-regression analyses and cal-
culated the relevant ORs for the covariates as the exponent
of the point estimates[26]. The point estimates and 95%
CI around denote the expected change in the pooled effect
size when the covariates are considered. The OR of the
point estimates and 95% CI confer the likelihood of the
covariate affecting individual trial outcomes. We addi-
tionally pooled all placebo-controlled trials and evaluated
effect sizes at 1 year and at 3 months. For head-to-head tri-
als of bupropion versus NRT, we conducted pooled ran-
dom-effects analyses at 1 year and at 3 months. For
varenicline trials, we conducted pooled random-effects
analyses of varenicline versus placebo at 1 year and at 3
months and for head-to-head trials of varenicline versus
bupropion at 1 year and at 3 months. Head-to-head trials
provide the strongest inferences regarding intervention
superiority[27]. However, in the absence of head-to-head
trials of varenicline versus NRT, we conducted indirect
comparisons of these interventions versus placebo using
methods described by Bucher et al and conducted z-tests
to confirm[28]. This method maintains the randomiza-
tion from each trial and compares the summary estimates
of pooled interventions with CIs. We calculated adverse
events, where reported, using Peto's Odds Ratio [OR] with
95% CIs[29]. Analyses were conducted using StatsDirect
(version 2.5.2) and Comprehensive Meta-analysis (ver-
sion 2).
Results
We found 70 RCTs examining NRT versus control inter-
ventions (See Figure 1 and Additional File 1), [30-99] 49
of which compared NRT to placebo
[30,32,34,35,38,39,43,44,46,48,50,54,56-59,62,64-69,
71-82,84-87,89-91,93,94,96,98,99] thirty one studies
compared NRT to other controlled groups (See table 1)
[31,33,36,37,40-42,45,49,51-53,55,61,63,70,83,88,92,
95,97] and 1 study uses both placebo and no intervention
as control group[47].
Thirty-three studies evaluated NRT gum [30-49,51-
53,55,61,63,64,71,83,87,95,96,98,99], 23 evaluated NRT
patch [50,56,57,60,62,65,67-70,72,76,78-80,82,84,86,
88,90,92,94,97]. The remaining studies evaluated the effi-
cacy of nicotine inhalers, nasal spray or lozenges
[54,58,59,66,73-75,77,81,85,89,91,93].
All of the studies provided sufficient details to evaluate
NRT versus control at 1 year [30-99]. Fifty-nine provided
sufficient details to evaluate NRT versus control at or
about 3 months[30-33,36,37,39-41,44,47,49-54,56-59,
43,59-61,63-86,88-96,98,99].
We also found 11 studies evaluating bupropion versus
placebo [5,6,8,82,100-106] and one RCT evaluating
bupropion with no intervention[97] (See Figure 1 and
Additional File 2). Further, 2 of these evaluated bupro-
pion versus NRT [82,97].
Finally, we identified 4 studies evaluating varenicline ver-
sus placebo (See Figure 1 and Additional File 3) [5,6,8,9].
Of these, 3 also evaluated varenicline versus bupro-
pion[5,6,8]. Agreement on original inclusion of all trials
was excellent (ϕ = 0.88).
Quality of methodological reporting
Of the 70 trials assessing NRT versus controls, studies were
varied in reporting important methodological features,
including: sequence generation (22/70), allocation con-
cealment (11/70), blinding status (64/70), appropriate
blinding (45/70), intention-to-treat (67/70), and appro-
priate descriptions of loss to follow up (44/70).
Studies assessing bupropion versus controls were simi-
larly varied in reporting, including: sequence generation
(4/12), allocation concealment (4/12), blinding statusBMC Public Health 2006, 6:300 http://www.biomedcentral.com/1471-2458/6/300
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(11/14), intention to treat (12/12) and appropriate
descriptions of loss to follow up (10/12).
The 4 studies assessing varenicline appropriately reported
the methodological criteria, except 1 study that did not
report the method of sequence generation[9].
Meta-analysis
NRT
We combined 70 trials (total n = 28,343) assessing NRT
versus controls at 1 year. The pooled OR of smoking ces-
sation favored NRT over controls (OR 1.71,95% CI, 1.55–
1.88, P =< 0.0001, I2 = 26.5%, Heterogeneity P = 0.02, See
Figure 2). This was consistent when evaluating only pla-
cebo controlled NRT trials (49 trials, n = 21,512, OR 1.78,
95% CI, 1.60–1.99, P =< 0.0001, I2 27.4%, Heterogeneity
P = 0.04) or when evaluating with cessation as sustained
abstinence (52 trials, total n = 22,704, OR 1.72 95% CI,
1.54–1.93, P =< 0.0001, I2 = 29.4%, Heterogeneity P =
0.02) or point prevalence (31 trials, n = 10,686, OR 1.53,
95% CI, 1.30–1.81, P = 0.01, I2 = 46%, Heterogeneity P =
0.01). This was also consistent whether one evaluated
NRT gum (33 trials, total n = 12,245, OR 1.60, 95% CI,
1.37–1.86, P =< 0.0001, I2 = 35.8%, Heterogeneity P =
0.02) or NRT patch (23 trials, total n = 11,108, OR 1.63,
95% CI, 1.41–1.89, P =< 0.0001, I2 = 12.3%, Heterogene-
ity P = 0.24).
Fifty-nine trials (total n = 25,294) provided sufficient
details to determine short-term effects of NRT on smoking
cessation, as determined at 3 months. The pooled OR of
the 59 trials was 1.98 (95% CI, 1.77–2.21, P =< 0.0001, I2
= 55.5%, Heterogeneity P =< 0.0001, See Figure 3). The
superiority of NRT over controls was consistent whether
one evaluated placebo-controlled trials (42 trials, total n
= 19,216, OR 2.11, 95% CI, 1.86–2.40, P =< 0.0001, I2 =
57.6%, Heterogeneity P =< 0.001), sustained abstinence
(41 trials, total n = 19,854, OR 2.04, 95% CI, 1.80–2.31,
Flowcharts of study searches Figure 1
Flowcharts of study searches.BMC Public Health 2006, 6:300 http://www.biomedcentral.com/1471-2458/6/300
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P =< 0.0001, I2 = 58%, Heterogeneity P =< 0.0001) or
point prevalence at 3 months (21 trials, total n = 6,453,
OR 1.78, 95% CI, 1.47–2.14, P =< 0.0001, I2 = 42.4, Het-
erogeneity P = 0.004). Studies assessing gum versus con-
trols at 3 months (24 trials, total n = 9,347) yielded an OR
of 1.71 (95% CI, 1.41–2.07, P =< 0.0001, I2 = 62%, Het-
erogeneity P =< 0.0001) and studies assessing patch versus
controls (21 trials, total n = 10,957) yielded an OR of 1.93
(95% CI, 1.67–2.24, P =< 0.0001, I2 = 35%, Heterogeneity
P = 0.05).
Bupropion
We evaluated the effect of bupropion on smoking cessa-
tion relative to adequate controls at 1 year in 12 trials
(total n = 5,228, See Figure 4). The pooled OR was 1.56
(95% CI, 1.10–2.21, P = 0.01, I2 = 71.5%, Heterogeneity P
=< 0.001). This effect was consistent whether examining
placebo-controls (11 trials, total n = 5,148, OR 1.64, 95%
CI, 1.16–2.30, P =< 0.001, I2 = 72%, Heterogeneity P =
0.001), sustained abstinence (11 trials, total n = 4,613,
OR 1.52, 95% CI, 1.04–2.23, P =< 0.0001, I2 = 73.6%,
Heterogeneity P = 0.0001), or point prevalence (10 trials,
total n = 4,845, OR 1.56, 95% CI, 1.13–2.16, P =< 0.0001,
I2 = 75.1%, Heterogeneity P =< 0.0001).
When we evaluated the effect of bupropion on placebo at
3 months (11 trials, total n = 5,148), the OR was 2.13
(95% CI, 1.72–2.64, P =< 0.0001, I2 = 53.6%, Heterogene-
ity P = 0.01, See Figure 5). This effect was consistent across
sustained abstinence measures (8 trials, total n = 4,143,
OR 2.18, 95% CI, 1.67–2.86, P =< 0.0001, I2 = 63.5%,
Heterogeneity P = 0.008) and point prevalence measures
(9 trials, total n = 4,765, OR 2.11, 95% CI, 1.77–2.52, P
=< 0.0001, I2 = 38.8%, Heterogeneity P = 0.10).
Varenicline
We pooled 4 studies assessing the effect of varenicline ver-
sus placebo at 1 year (total n = 2,528, See Figure 6). The
pooled OR is 2.96 (95% CI, 2.12–4.12, P =< 0.0001, I2 =
20.5%, Heterogeneity P = 0.20). This effect was consistent
with short-term cessation effects (4 trials, total n = 2,528,
OR 3.75, 95% CI, 2.65–5.30, P =< 0.0001, I2 = 57.7%,
Heterogeneity P = 0.06, See Figure 7). We explained heter-
ogeneity in this analysis through the inclusion of the
dose-ranging studies[8,9].
Comparisons
Two trials evaluated the superiority of NRT versus bupro-
pion at 1 year [82,97] (total n = 548, See Figure 8) and
found a pooled OR of 1.14 (95% CI, 0.20–6.42, P = 0.88,
I2 = 59%, Heterogeneity P = 0.11. Only 1 trial provided
details on cessation rates at 3 months and favored bupro-
pion (OR 2.66, 95% CI 1.70–4.15, P =< 0.001)[82]. Three
trials evaluated the effectiveness of varenicline versus
bupropion at 1 year[5,6,8] and yielded a pooled OR of
1.58 (95% CI, 1.22–2.05, P = 0.001, I2 = 0%, Heterogene-
ity P = 0.81, See Figure 9) in favor of varenicline. These
same trials provided consistent data at 3 months (OR
1.61, 95% CI, 1.16–2.21, P = 0.004, I2 = 56.1%, Heteroge-
neity P = 0.10, See Figure 10).
Using indirect comparisons[28], we found that bupro-
pion was not superior to NRT when compared to a pla-
cebo control at 1 year (OR 0.92, 95% CI 0.64–1.32, test
for difference, P = 0.65). This was similar for 3-month
data (OR 1.01, 95% CI 0.79–1.29, test for difference
0.94). We found that varenicline was superior to NRT
when compared to placebo controls (OR 1.66, 95% CI,
1.17–2.36, test for difference P = 0.004, See Figure 11) or
Table 1: Univariable meta-regression of NRT studies
Covariates Point 
estimate
Lower 95% 
limit
Upper 95% 
limit
OR Lower 95% 
limit
Upper 95% 
limit
p-value
Placebo 0.13 -0.03 0.31 1.13 0.97 1.36 0.12
Sequence 
generation
-0.15 -0.32 0.006 0.86 0.72 1.00 0.06
Allocation 
concealment
-0.20 -0.39 0.01 0.81 0.67 1.01 0.03
Gum -0.18 -0.32 -0.02 0.83 0.72 0.98 0.02
Patch 0.0007 -0.15 0.16 1.00 0.86 1.17 0.99
CO 0.52 0.24 0.80 1.68 1.27 2.22 0.0002
Cotinine -0.21 -0.37 -0.05 0.81 0.69 0.95 0.007
Serum -0.36 -0.75 0.01 0.69 0.47 1.01 0.06
Urine -0.36 -0.70 -0.02 0.69 0.49 0.98 0.03
Planned to quit 0.12 -0.02 0.27 1.12 0.98 1.30 0.10
Legend. The point estimate and 95% CIs estimate the unit change in the effect size, whenever the predicted covariate is present. The OR for the 
point estimates and 95% CI denote the likelihood of covariate affecting the trial effect size.BMC Public Health 2006, 6:300 http://www.biomedcentral.com/1471-2458/6/300
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Random Effects Meta-Analysis Figure 2
Random Effects Meta-Analysis. NRT vs. Controls at 12 months. I2 = 26.5%.
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Schneider N1 1.481 0.541 4.057 0.765 0.444
British Thoracic Society 0.836 0.533 1.312 -0.777 0.437
 Russell MAH 2.026 1.379 2.978 3.595 0.000
Jarvik ME 1.847 0.461 7.397 0.867 0.386
Fagerstrom K 3.624 1.301 10.093 2.463 0.014
Hjalmarson A1 2.144 1.087 4.230 2.201 0.028
Hall S1 2.035 0.783 5.289 1.458 0.145
Clavel 4.773 1.910 11.932 3.344 0.001
Hall S2 2.822 1.329 5.994 2.700 0.007
Sutton 1 5.313 0.701 40.255 1.617 0.106
Campbell L1 1.416 0.599 3.350 0.792 0.428
Sutton 2 2.703 0.509 14.357 1.167 0.243
Tonneson 1 2.124 0.928 4.858 1.784 0.074
Harackiewicz JM 0.887 0.326 2.408 -0.236 0.814
Blondal T1 1.850 0.989 3.460 1.926 0.054
Hughes JR 1.480 0.712 3.076 1.050 0.294
Gilbert JR 0.858 0.300 2.453 -0.285 0.776
Killen JD  1.362 1.025 1.811 2.129 0.033
Segnan N 1.402 0.712 2.762 0.977 0.329
Tonneson 2 5.829 1.660 20.470 2.751 0.006
Campbell L2 0.977 0.497 1.919 -0.068 0.946
Zelman DC 1.460 0.679 3.140 0.969 0.332
Mcgovern PG 1.168 0.704 1.937 0.600 0.548
Sutherland 3.171 1.500 6.704 3.022 0.003
Pirie PL 1.299 0.810 2.082 1.085 0.278
Nebot M 1.269 0.405 3.976 0.408 0.683
Tonneson 3 3.424 1.413 8.296 2.726 0.006
Sachs DP 3.195 1.467 6.960 2.924 0.003
Hurt RD 2.298 1.199 4.407 2.505 0.012
Fowler G 1.481 1.028 2.132 2.111 0.035
Hjalmarson A2 2.179 1.153 4.119 2.399 0.016
Niaura R  1.345 0.349 5.188 0.430 0.667
Fortmann SP 1.392 1.017 1.906 2.064 0.039
Kornitzer M 0.943 0.415 2.144 -0.141 0.888
Dale LC 1.403 0.472 4.175 0.609 0.543
Stapleton JA 2.136 1.273 3.582 2.876 0.004
Herrera N 3.404 1.689 6.861 3.426 0.001
Schneider N2 2.563 1.166 5.634 2.341 0.019
Puska P 1.506 0.856 2.650 1.421 0.155
Campbell LA 1.582 0.800 3.132 1.318 0.188
Hall SM 0.869 0.461 1.636 -0.436 0.663
Leischow SJ 2.121 0.767 5.869 1.448 0.148
Cinciripini PM 2.143 0.712 6.451 1.355 0.175
Schneider N3 1.753 0.733 4.191 1.261 0.207
Paoletti P 4.349 1.486 12.729 2.683 0.007
Killen JD 1.107 0.593 2.067 0.318 0.750
Blondal T 1.695 0.775 3.705 1.322 0.186
Richmond RL 2.305 1.165 4.561 2.399 0.016
Hjalmarson A3 1.844 1.007 3.376 1.983 0.047
Daughton D 1.816 0.943 3.498 1.785 0.074
Perng RP 4.143 0.999 17.178 1.959 0.050
Niaura R 0.688 0.224 2.107 -0.656 0.512
Tonneson 4 1.498 1.147 1.955 2.969 0.003
Jorenby DE 1.830 0.828 4.047 1.493 0.135
Blondal T 2 3.034 1.500 6.138 3.087 0.002
Bolliger CT 1.362 0.627 2.959 0.781 0.435
Garvey AJ 2.487 1.426 4.337 3.209 0.001
Wisborg 1.086 0.540 2.183 0.231 0.817
Tonneson 5 0.673 0.185 2.449 -0.601 0.548
Wallstrom M 1.629 0.854 3.105 1.482 0.138
Bohadana A  1.488 0.875 2.530 1.467 0.142
Glover ED 2.039 0.959 4.336 1.851 0.064
Shiffman S 2.279 1.692 3.070 5.419 0.000
Hand S 1.080 0.525 2.226 0.210 0.834
Wennike P 3.128 1.365 7.168 2.695 0.007
Glavas D 1.579 0.614 4.063 0.947 0.344
Molyneux A 3.395 1.178 9.780 2.264 0.024
Cooper TV 1.168 0.560 2.438 0.415 0.678
Batra A 2.920 1.264 6.744 2.509 0.012
Swanson NA 0.683 0.162 2.868 -0.521 0.602
1.713 1.556 1.886 10.988 0.000
0.01 0.1 1 10 100
Favours Control Favours NRTBMC Public Health 2006, 6:300 http://www.biomedcentral.com/1471-2458/6/300
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Random Effects Meta-Analysis Figure 3
Random Effects Meta-Analysis. NRT vs. Controls at 3 months. I2 = 55.5%.
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Valuep-Value
British Thoracic Society 0.848 0.609 1.181 -0.975 0.330
 Russell MAH 1.571 1.182 2.088 3.113 0.002
Schneider N1 1.676 0.728 3.859 1.215 0.224
Fagerstrom K 3.583 1.381 9.300 2.623 0.009
Clavel 3.279 1.830 5.874 3.992 0.000
Hall S1 3.048 1.177 7.894 2.296 0.022
Hall S2 1.544 0.791 3.014 1.272 0.203
Sutton 39.651 2.328 675.233 2.544 0.011
Tonneson 1 2.684 1.252 5.756 2.537 0.011
Harackiewicz JM 0.885 0.385 2.035 -0.287 0.774
Blondal T1 2.137 1.179 3.873 2.503 0.012
Killen JD 1990 1.416 1.111 1.804 2.810 0.005
Tonneson 2 12.430 4.304 35.898 4.657 0.000
Segnan N 1.374 0.710 2.659 0.943 0.346
Sutherland 3.418 1.845 6.334 3.905 0.000
Pirie PL 2.291 1.548 3.392 4.141 0.000
Nebot M 1.128 0.502 2.539 0.292 0.770
Mcgovern PG 0.982 0.604 1.596 -0.073 0.942
Tonneson 3 2.569 1.278 5.161 2.650 0.008
Sachs DP 2.321 1.315 4.097 2.903 0.004
Fowler G 1.786 1.364 2.339 4.213 0.000
Hjalmarson A1 2.702 1.534 4.757 3.443 0.001
Niaura R  1.412 0.685 2.910 0.934 0.350
Hurt RD 2.769 1.533 5.000 3.378 0.001
Stapleton JA 2.104 1.457 3.039 3.966 0.000
Herrera N 4.895 2.470 9.701 4.551 0.000
Schneider N2 3.389 1.809 6.349 3.812 0.000
Puska P 1.667 1.027 2.705 2.069 0.039
Fortmann SP 1.611 1.216 2.135 3.320 0.001
Kornitzer M 1.398 0.688 2.842 0.925 0.355
Campbell LA 1.407 0.796 2.487 1.176 0.240
Hall S3 1.316 0.753 2.300 0.963 0.335
Leischow SJ 5.004 2.267 11.049 3.985 0.000
Cinciripini PM 3.151 1.061 9.357 2.067 0.039
Schneider N3 2.888 1.353 6.165 2.741 0.006
Paoletti P 4.171 1.529 11.378 2.789 0.005
Richmond RL 2.868 1.632 5.043 3.661 0.000
Hjalmarson A2 1.978 1.132 3.457 2.394 0.017
Blondal T2 2.713 1.318 5.583 2.710 0.007
Killen JD 1.635 0.984 2.715 1.898 0.058
Daughton D 2.382 1.349 4.204 2.993 0.003
Perng RP 3.298 1.164 9.338 2.247 0.025
Tonneson 4 1.909 1.549 2.354 6.057 0.000
Blondal T3 1.764 1.010 3.079 1.997 0.046
Jorenby 1.365 0.746 2.500 1.009 0.313
Niaura R 1.176 0.548 2.528 0.416 0.677
Wisborg 1.342 0.776 2.320 1.054 0.292
Tonneson 5 1.106 0.529 2.310 0.268 0.789
Wallstrom M 2.511 1.445 4.363 3.267 0.001
Bohadana A  1.612 1.069 2.430 2.278 0.023
Bolliger CT 3.406 1.091 10.634 2.110 0.035
Glover ED 2.431 1.317 4.489 2.840 0.005
Shiffman S 2.469 1.986 3.070 8.132 0.000
Hand S 1.370 0.748 2.511 1.020 0.308
Molyneux A 2.368 0.917 6.120 1.780 0.075
Wennike P 13.880 1.799 107.117 2.523 0.012
Glavas D 2.647 1.132 6.192 2.245 0.025
Cooper TV 1.294 0.742 2.256 0.908 0.364
Batra A 3.052 0.966 9.649 1.900 0.057
1.984 1.779 2.213 12.287 0.000
0.01 0.1 1 10 100
Favours Control Favours NRTBMC Public Health 2006, 6:300 http://www.biomedcentral.com/1471-2458/6/300
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Random Effects Meta-Analysis Figure 4
Random Effects Meta-Analysis. Bupropion vs. Controls at 12 months. I2 = 71.5%.
Random Effects Meta-Analysis Figure 5
Random Effects Meta-Analysis. Bupropion vs. Controls at 3 months. I2 = 53.6%.BMC Public Health 2006, 6:300 http://www.biomedcentral.com/1471-2458/6/300
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to all controls at 1 year (OR 1.73, 95% CI 1.22–2.45, test
for difference P = 0.001). This was also the case when we
examined 3-month data for placebo controls (OR 1.78,
95% CI, 1.23–2.57, test for difference P = 0.002, See Fig-
ure 12) or all controls (OR 1.89, 95% CI, 1.31–2.73, test
for difference P = 0.0006).
Meta-regression
We anticipated variable between-study heterogeneity,
considering the interventions used, methodological issues
and measurement tools. Table 1 displays the covariates
predicting heterogeneity in the primary outcomes of the
NRT analysis using meta-regression. In this analysis, sig-
nificant predictors of heterogeneity included: allocation
concealment, use of NRT gum; and, methods of chemical
confirmation (CO, cotinine, and urine markers). Using
sensitivity analysis, only studies (n = 3[49,53,71]) using
urine as a marker were significantly different from the
pooled estimate (P = 0.03), however, all but 1 of these
studies also used CO as a chemical marker (P = 0.5)[49].
We additionally examined covariates in the bupropion tri-
als (See Table 2). We found sequence generation was a sig-
nificant contributor to heterogeneity. In addition, the
chemical marker covariates contributed to heterogeneity.
We did not conduct a meta-regression on the varenicline
studies, given the small number of studies.
Adverse events
Additional File 1 displays the common adverse events
associated with NRT. Inadequate detail was provided for
pooling. For NRT trials, we found that the following
Random Effects Meta-Analysis Figure 6
Random Effects Meta-Analysis. Varenicline vs. Placebo at 12 months. I2 = 20.5%.
Random Effects Meta-Analysis Figure 7
Random Effects Meta-Analysis. Varenicline vs. Placebo at 3 months. I2 = 57.7%.BMC Public Health 2006, 6:300 http://www.biomedcentral.com/1471-2458/6/300
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adverse events were reported significantly more often in
active groups than control groups: mouth or throat irrita-
tion (n = 12); skin irritation (n = 11); nausea/vomiting (n
= 10); coughing (n = 9); hiccoughs (n = 6); dyspepsia (n =
4); watering of eyes (n = 3); headaches (n = 3); heart pal-
pitations (n = 3); sneezing (n = 3); sleep disturbances and
dream abnormalities (n = 2); insomnia (n = 2); rhinitis (n
= 2); vertigo (n = 1); taste disturbances (n = 1) and muscle
aches (n = 1).
For bupropion trials, the following adverse events were
reported significantly more in the active groups than con-
trol groups: dry mouth (9 trials[5,6,8,82,102-106], n =
4,885, OR 1.90, 95% CI, 1.50–2.42, P =< 0.0001); insom-
nia (10 trials[5,6,8,82,101-106], n = 4,775, OR 2.02, 95%
CI, 1.53–2.68, P =< 0.0001); gastrointestinal upset (7 tri-
als[5,6,8,82,104-106], n = 4,026, OR 1.34, 95% CI, 1.06–
1.70, P = 0.01) and constipation (6 trials[5,6,8,104-106],
n = 3,622, OR 2.48, 95% CI, 1.62–3.80, P =< 0.0001).
Other severe events associated with trial participants in
the active arms were: septic shock; grand mal seizure;
sleep disorders; and anxiety. These were single cases and
did not achieve significance.
For varenicline trials, the following adverse events were
reported significantly more often than in the placebo
groups: nausea (4 trials [5,6,8,9], n = 2,506, OR 3.17,
2.35–4.29, P =< 0.0001); flatulence (2 trials[5,9], n =
1,323, OR 2.04, 95% CI, 1.16–3.57, P = 0.01); and, con-
stipation (4 trials[5,6,8,9], n = 2,506, OR 2.57, 95% CI,
1.21–5.45, P =< 0.0001). Other, severe events that
occurred in the active groups included: atrial fibrillation,
pneumonia, possible stroke, chest pain, and elevated
blood pressure. These were, however, single cases and did
not achieve significance.
Random Effects Meta-Analysis Figure 8
Random Effects Meta-Analysis. NRT vs. Bupropion at 12 months. I2 = 59%.
Random Effects Meta-Analysis Figure 9
Random Effects Meta-Analysis. Varenicline vs. Bupropion at 12 months. I2 = 0%.BMC Public Health 2006, 6:300 http://www.biomedcentral.com/1471-2458/6/300
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Discussion
In this study we present the results of three main meta-
analyses examining the effectiveness of various pharma-
cological strategies to improve smoking cessation. Our
primary meta-analyses specifically examined the effective-
ness of NRT versus control, bupropion versus control, and
varenicline versus bupropion or placebo. We demon-
strated the consistent effectiveness of each intervention in
short-term and long-term smoking cessation.
Our findings confirm the effectiveness of two established
pharmacological therapies, NRT and bupropion, to
improve cessation rates. The primary new information
from this review is the evidence of effectiveness of vareni-
cline. This modality of treatment was identified to be
more effective than placebo, bupropion and in indirect
comparisons with NRT. However, this meta-analysis con-
sisted of the fewest studies and although the studies were
well reported and apparently well conducted, further
studies comparing varenicline versus either NRT or bupro-
pion will strengthen inferences about the superiority of
this intervention. Nevertheless the initial findings are sug-
gestive of the potential superiority of this latest pharmaco-
logical intervention.
This review has several strengths and some limitations
that deserve mention. The strengths of this review include
the comprehensive search strategy that improved the like-
lihood of identifying all relevant studies. Duplicate extrac-
tion of data reduced the potential for bias in this
component of the synthesis process. By limiting this
review to randomized trials we ensured that the included
studies would have reduced likelihood of systematic error
and therefore have high internal validity. Our use of meta-
Random Effects Meta-Analysis Figure 10
Random Effects Meta-Analysis. Varenicline vs. Bupropion at 3 months. I2 = 56.1%.
Indirect comparison between Varenicline and NRT vs Placebo at 12 months Figure 11
Indirect comparison between Varenicline and NRT vs Placebo at 12 months. Bucher et al. indirect comparison 
methods [28].BMC Public Health 2006, 6:300 http://www.biomedcentral.com/1471-2458/6/300
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regression to identify sources of heterogeneity in the
meta-analyses is a strength and demonstrated that several
of the a priori chosen covariates were predictors of hetero-
geneity. While our primary endpoint was one-year cessa-
tion, as defined by the study, we evaluated the robustness
of these findings through multiple sensitivity analyses
which included one-year sustained cessation, a strong pre-
dictor of sustained smoking cessation[108,109]. Unlike
some meta-analyses and systematic reviews of smoking
cessation therapies [3,4,12-19], we included only studies
that chemically confirmed the cessation of smoking at the
specific time-points. This is a strength of our analysis as
we demonstrated that even the different chemical markers
for cessation can contribute greatly to between-study dif-
ferences. Our meta-regression analysis indicates that the
type of chemical markers employed yields greater variabil-
ity of effects between studies over more commonly inves-
tigated covariates, such as methodological issues[110].
Limitations of this meta-analysis include the potential for
publication bias, specifically the possibility that small
negative studies would not be published. We included
only published trials so it is possible that other trials have
been conducted and never published. However, it is
unlikely that the presence of these studies would have
altered the findings of the NRT meta-analysis given the
large number of studies included. Similarly, since vareni-
cline is a new agent and the studies synthesized were the
first clinical trials evaluating its effectiveness, it is improb-
able other negative studies exist. We also limited our
search to English language databases (although we would
include non-English articles if identified) so the possibil-
ity of quality studies in other languages does exist. We
used both direct and indirect comparisons to evaluate the
relative effectiveness of agents. Head-to-head trials pro-
vide the strongest inferences regarding intervention supe-
riority[27]. However, in the absence of head-to-head
trials, specifically NRT versus varenicline, we conducted
indirect comparisons. We used the indirect comparison
method proposed by Bucher et al., which respects the
principle of randomization between trials [28]. The utility
of indirect comparisons is debatable and some evidence
suggests that indirect comparisons may provide mislead-
ing measures of superiority, although the direction of bias
Indirect comparison between Varenicline and NRT vs Placebo at 3 months Figure 12
Indirect comparison between Varenicline and NRT vs Placebo at 3 months. Bucher et al. indirect comparison meth-
ods [28].
Table 2: Univariable meta-regression of bupropion studies.
Covariates Point 
estimate
Lower 95% 
limit
Upper 95% 
limit
OR Lower 95% 
limit
Upper 95% 
limit
p-value
Placebo 2.00 -0.14 4.15 7.38 0.86 63.4 0.07
Sequence 
generation
-0.46 -0.84 -0.08 0.63 0.43 0.92 0.01
Allocation 
concealment
-0.20 -0.55 0.14 0.81 0.57 1.15 0.25
CO 0.76 0.06 1.46 2.13 1.06 4.30 0.03
Cotinine -0.76 -1.46 -0.06 0.46 0.23 0.94 0.03
Planned to quit 0.13 -0.22 0.48 1.13 0.80 1.61 0.46
Legend. The point estimate and 95% CIs estimate the unit change in the effect size, whenever the predicted covariate is present. The OR for the 
point estimates and 95% CI denote the likelihood of covariate affecting the trial effect size.BMC Public Health 2006, 6:300 http://www.biomedcentral.com/1471-2458/6/300
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cannot be assumed until direct comparison trials have
been completed[111]. Figure 8 displays an interesting
methodologic outcome related to choosing random-
effects models over a fixed-effects model for meta-analy-
ses. The pooled OR of the two head-to-head trials is a non-
significant difference of 1.14 (95% CI, 0.20–6.42, P =
0.88) when using the random effects model, as planned in
our protocol [82,97]. However, had we used a fixed effects
model, this would have resulted in a significant pooled
OR of 1.84 (95% CI, 1.11–3.06, P = 0.02). We believe that
this is due to the very small number of trials included (n
= 2) [82,97], where one trial is much larger than the other
(n of 488 compared to an n of 60). Finally, our meta-anal-
yses did not examine in detail other aspects of therapy,
such as compliance and tolerance, which may influence
real life clinical effectiveness.
There are several important implications of these meta-
analyses. Identifying effective mechanisms to improve
smoking cessation is essential. Smoking is the number
one preventable cause of death in the world[1]. Approxi-
mately one out of every two long-term smokers will die of
a smoking related death[112]. Furthermore, smoking ces-
sation has been clearly demonstrated to reduce the likeli-
hood of future morbidity. Smoking cessation in
individuals with chronic obstructive lung disease reduces
the deterioration of FEV1[113]. Smoking cessation also
reduces the likelihood of developing several smoking
related cancers[109]. Smoking cessation in patients with
coronary artery disease has been consistently shown to be
associated with dramatically improved survival. Observa-
tional studies demonstrate that smokers who quit smok-
ing after a myocardial infarction have mortality rates
approximately 40% less than those that continue to
smoke, suggesting that smoking cessation could be one of
the most effective therapies to improve survival in this
group of patients[114]. Former smokers have also been
demonstrated to have considerably lower rates of cere-
brovascular disease than ongoing smokers[115].
Conclusion
The findings of this review point the direction for future
studies. It is interesting that the three modalities exam-
ined have distinct biological mechanisms of action. NRT
presumably works by reducing symptoms of nicotine
withdrawal, thereby increasing the likelihood of smoking
cessation. Bupropion is a weak dopamine and nor-epine-
phrine reuptake inhibitor. One of the primary symptoms
of smoking cessation has been depressive symptoms and
it has been hypothesized that smokers may be increasing
central dopamine levels by reducing monoamine oxidase
inhibitor activity[116]. The mechanism of action of
bupropion, therefore, may be to maintain central levels of
dopamine through the process of cessation, although its
effectiveness has been identified to be independent of
symptoms of depression[102]. Varenicline is a nicotinic
acetylcholine receptor partial agonist. The authors of one
the studies demonstrating its efficacy comment that "Par-
tial agonists at this (receptor) could stimulate the release
of sufficient dopamine to reduce craving and withdrawal
while simultaneously acting as a partial antagonist by
blocking the binding and consequent reinforcing effects
of smoked nicotine[5]." Regardless of the exact mecha-
nism of action of the three modalities, it is clear they are
distinct and suggest the possibility of combination ther-
apy or therapy targeted on the particular type of symp-
toms experienced during cessation. Future studies could
examine these options, given that despite the effectiveness
of these therapies rates of smoking remain high at one
year in the treatment groups [82]. Furthermore, given the
benefits described of smoking cessation as secondary pre-
vention, the use of these cessation modalities in patients
with active smoking related disease warrants further study
[117]. Future studies should further examine the safety
and effectiveness in reducing morbidity and mortality of
all three of these modalities in patients with active smok-
ing related disease.
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